Aethlon Medical, Inc. (AEMD) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated February 12, 2026, serves as a current report for Aethlon Medical, Inc., a Nevada corporation headquartered in San Diego, California. The filing primarily addresses the Company's financial results for the quarter ended December 31, 2025, pursuant to Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The report explicitly states that the detailed financial results are contained within a press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the text of this 8-K.
Material Changes
No specific material changes versus the prior comparable period are detailed in the body of this filing. The document functions as a notification that the Q4 2025 results have been issued, deferring the specific comparative data to the referenced press release.
Guidance, Outlook, and Risks
The filing contains no explicit guidance, outlook, or management commentary regarding future performance within the text provided. It includes standard legal disclaimers stating that the information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 12, 2026) for actual Q4 2025 revenue, net loss, and cash position figures.
- Verify the Company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones for the Company's blood purification technologies mentioned in the full release.
- Confirm if the Company provided updated full-year 2026 guidance in the referenced press release.